Table 2 Demographic and clinical characteristics of enrolled patients and their association with history of anti-tuberculosis treatment
Retreatment (n = 697) | New (n = 3720) | All (n = 4417) | OR (95% CI) | p-value | aOR (95% CI) | p-value | |
|---|---|---|---|---|---|---|---|
Age (years) | |||||||
15–34 | 68 (9.8%) | 666 (17.9%) | 734 (16.6%) | ||||
35–59 | 275 (39.5%) | 1318 (35.4%) | 1593 (36.1%) | 2.04 (1.54–2.71) | 0.000 | 1.85 (1.39–2.47) | 0.000 |
≥ 60 | 354 (50.85) | 1736 (46.7%) | 2090 (47.3%) | 2.00 (1.52–2.63) | 0.000 | 1.94 (1.47–2.56) | 0.000 |
Male gender | 495 (71.0%) | 2130 (57.3%) | 2625 (59.4%) | 1.83 (1.53–2.18) | 0.000 | 1.75 (1.46–2.09) | 0.000 |
Pulmonary involvement | 669 (96.0%) | 3465 (93.1%) | 4134 (93.6%) | 1.76 (1.18–2.62) | 0.006 | 1.49 (0.99–2.23) | 0.056 |
Drug-resistant TB | 174 (25.0%) | 510 (13.7%) | 684 (15.5%) | 2.09 (1.72–2.55) | 0.000 | 2.13 (1.74–2.59) | 0.000 |
Notification year | |||||||
2015 | 193 (27.7%) | 1023 (27.5%) | 1216 (27.5%) | ||||
2016 | 163 (23.4%) | 1023 (27.5%) | 1186 (26.9%) | 0.85 (0.67–1.06) | 0.143 | ||
2017 | 160 (23.0%) | 821 (22.1%) | 981 (22.2%) | 1.03 (0.82–1.30) | 0.781 | ||
2018 | 181 (26.0%) | 853 (22.9%) | 1034 (23.4%) | 1.13 (0.90–1.41) | 0.300 | ||